Donald Smith

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Making sense of ENHANCE: ezetimibe (Zetia) lowers LDL cholesterol but doesn't decrease carotid intima-media thickness
    Donald Smith
    Lipids and Metabolism, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 75:143-7. 2008
  2. ncbi Abdominal diameter index: a more powerful anthropometric measure for prevalent coronary heart disease risk in adult males
    D A Smith
    Community and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Diabetes Obes Metab 7:370-80. 2005
  3. ncbi Treatment of the dyslipidemia of insulin resistance
    Donald A Smith
    Zena and Michael A Wiener Cardiovascular Institute, Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, Box 1014, 1 Gustave Levy Place, New York City, NY 10029 657, USA
    Med Clin North Am 91:1185-210, x. 2007
  4. ncbi Statin therapy for native and peri-interventional coronary heart disease
    D A Smith
    The Zena and Michael A Wiener Cardiovascular Institute and The Marie Josee and Henry R Kravis Center for Cardiovascular Health, The Mount Sinai Medical Center, New York, NY 10029, USA
    Curr Mol Med 6:589-602. 2006
  5. ncbi Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging
    Roberto Corti
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY 10029, USA
    Circulation 106:2884-7. 2002
  6. ncbi Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines
    Devin Mann
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Pharmacother 42:1208-15. 2008
  7. ncbi Preemployment drug screening in a large metropolitan medical center: a one-month trial
    D A Smith
    Mount Sinai Medical Center, New York, New York 10029
    J Gen Intern Med 6:558-60. 1991
  8. ncbi Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin
    G Dangas
    Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA
    Am J Cardiol 84:639-43. 1999
  9. ncbi Standard lipid profile
    Satish R Tiyyagura
    Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY 10029-6574, USA
    Clin Lab Med 26:707-32. 2006
  10. ncbi Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study
    Ira D Galin
    Am Heart J 151:e1. 2006

Detail Information

Publications14

  1. ncbi Making sense of ENHANCE: ezetimibe (Zetia) lowers LDL cholesterol but doesn't decrease carotid intima-media thickness
    Donald Smith
    Lipids and Metabolism, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 75:143-7. 2008
  2. ncbi Abdominal diameter index: a more powerful anthropometric measure for prevalent coronary heart disease risk in adult males
    D A Smith
    Community and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Diabetes Obes Metab 7:370-80. 2005
    ..The authors wished to compare the strength of association of several anthropometric measures of body size and fat distribution among themselves and in comparison with other known risk factors for prevalent coronary heart disease (CHD)...
  3. ncbi Treatment of the dyslipidemia of insulin resistance
    Donald A Smith
    Zena and Michael A Wiener Cardiovascular Institute, Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, Box 1014, 1 Gustave Levy Place, New York City, NY 10029 657, USA
    Med Clin North Am 91:1185-210, x. 2007
    ..This article explores the description, pathophysiology, and treatment of these atherogenic lipid abnormalities...
  4. ncbi Statin therapy for native and peri-interventional coronary heart disease
    D A Smith
    The Zena and Michael A Wiener Cardiovascular Institute and The Marie Josee and Henry R Kravis Center for Cardiovascular Health, The Mount Sinai Medical Center, New York, NY 10029, USA
    Curr Mol Med 6:589-602. 2006
    ....
  5. ncbi Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging
    Roberto Corti
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY 10029, USA
    Circulation 106:2884-7. 2002
    ..Our observations indicate that lipid-lowering therapy is associated with sustained vascular remodeling and emphasize the need for longer-term treatment...
  6. ncbi Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines
    Devin Mann
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann Pharmacother 42:1208-15. 2008
    ..Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001...
  7. ncbi Preemployment drug screening in a large metropolitan medical center: a one-month trial
    D A Smith
    Mount Sinai Medical Center, New York, New York 10029
    J Gen Intern Med 6:558-60. 1991
    ..The findings suggest that applicants for jobs in large medical centers in metropolitan areas are no different from those in other sectors of the economy with respect to illicit drug use...
  8. ncbi Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin
    G Dangas
    Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA
    Am J Cardiol 84:639-43. 1999
    ..Blood thrombogenicity was reduced with pravastatin in both genders; in addition, thrombin generation was gradually reduced in women to a level similar to that of men by 6 months of follow-up...
  9. ncbi Standard lipid profile
    Satish R Tiyyagura
    Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY 10029-6574, USA
    Clin Lab Med 26:707-32. 2006
    ....
  10. ncbi Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study
    Ira D Galin
    Am Heart J 151:e1. 2006
  11. ncbi Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging
    Roberto Corti
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Coll Cardiol 46:106-12. 2005
    ..No difference in vessel wall changes was seen between high and conventional doses of simvastatin. Changes in vessel wall parameters are more related to LDL-C reduction rather than to the dose of statin...
  12. ncbi New trends in lipid management: eight cases to consider
    Donald A Smith
    Department of Medicine and Community and Preventive Medicine, Box 1014, Mount Sinai Medical Center, 1 East 100th Street, New York, NY 10029-6574, USA
    Mt Sinai J Med 72:90-9. 2005
    ....
  13. ncbi American College of Endocrinology position statement on the insulin resistance syndrome
    Daniel Einhorn
    American College of Endocrinology
    Endocr Pract 9:237-52. 2003